355 related articles for article (PubMed ID: 28212825)
1. Inhibition of ubiquitin proteasome function prevents monocrotaline-induced pulmonary arterial remodeling.
Zhu Y; Wu Y; Shi W; Wang J; Yan X; Wang Q; Liu Y; Yang L; Gao L; Li M
Life Sci; 2017 Mar; 173():36-42. PubMed ID: 28212825
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Siah2 ubiquitin ligase ameliorates monocrotaline-induced pulmonary arterial remodeling through inactivation of YAP.
Wang Q; Shi W; Zhang Q; Feng W; Wang J; Zhai C; Yan X; Li M
Life Sci; 2020 Feb; 242():117159. PubMed ID: 31837334
[TBL] [Abstract][Full Text] [Related]
3. Resveratrol inhibits monocrotaline-induced pulmonary arterial remodeling by suppression of SphK1-mediated NF-κB activation.
Shi W; Zhai C; Feng W; Wang J; Zhu Y; Li S; Wang Q; Zhang Q; Yan X; Chai L; Liu P; Chen Y; Li M
Life Sci; 2018 Oct; 210():140-149. PubMed ID: 30179628
[TBL] [Abstract][Full Text] [Related]
4. Activation of AMPK prevents monocrotaline-induced pulmonary arterial hypertension by suppression of NF-κB-mediated autophagy activation.
Zhai C; Shi W; Feng W; Zhu Y; Wang J; Li S; Yan X; Wang Q; Zhang Q; Chai L; Li C; Liu P; Li M
Life Sci; 2018 Sep; 208():87-95. PubMed ID: 30009823
[TBL] [Abstract][Full Text] [Related]
5. Tetrandrine prevents monocrotaline-induced pulmonary arterial hypertension in rats through regulation of the protein expression of inducible nitric oxide synthase and cyclic guanosine monophosphate-dependent protein kinase type 1.
Wang X; Yang Y; Yang D; Tong G; Lv S; Lin X; Chen C; Dong W
J Vasc Surg; 2016 Nov; 64(5):1468-1477. PubMed ID: 26527422
[TBL] [Abstract][Full Text] [Related]
6. Salvianolic acid A attenuates vascular remodeling in a pulmonary arterial hypertension rat model.
Chen YC; Yuan TY; Zhang HF; Wang DS; Yan Y; Niu ZR; Lin YH; Fang LH; Du GH
Acta Pharmacol Sin; 2016 Jun; 37(6):772-82. PubMed ID: 27180980
[TBL] [Abstract][Full Text] [Related]
7. Activation of Autophagy Induces Monocrotaline-Induced Pulmonary Arterial Hypertension by FOXM1-Mediated FAK Phosphorylation.
Zhai C; Zhang N; Wang J; Cao M; Luan J; Liu H; Zhang Q; Zhu Y; Xue Y; Li S
Lung; 2022 Oct; 200(5):619-631. PubMed ID: 36107242
[TBL] [Abstract][Full Text] [Related]
8. Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension.
Behringer A; Trappiel M; Berghausen EM; Ten Freyhaus H; Wellnhofer E; Odenthal M; Blaschke F; Er F; Gassanov N; Rosenkranz S; Baldus S; Kappert K; Caglayan E
Naunyn Schmiedebergs Arch Pharmacol; 2016 Apr; 389(4):369-79. PubMed ID: 26742933
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib alleviates experimental pulmonary arterial hypertension.
Kim SY; Lee JH; Huh JW; Kim HJ; Park MK; Ro JY; Oh YM; Lee SD; Lee YS
Am J Respir Cell Mol Biol; 2012 Nov; 47(5):698-708. PubMed ID: 22842494
[TBL] [Abstract][Full Text] [Related]
10. Ang-(1-7) might prevent the development of monocrotaline induced pulmonary arterial hypertension in rats.
Chen L; Xiao J; Li Y; Ma H
Eur Rev Med Pharmacol Sci; 2011 Jan; 15(1):1-7. PubMed ID: 21381494
[TBL] [Abstract][Full Text] [Related]
11. Pulmonary arterial hypertension induced by a novel method: Twice-intraperitoneal injection of monocrotaline.
Zhuang W; Lian G; Huang B; Du A; Xiao G; Gong J; Xu C; Wang H; Xie L
Exp Biol Med (Maywood); 2018 Aug; 243(12):995-1003. PubMed ID: 30099957
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of HDAC1 alleviates monocrotaline-induced pulmonary arterial remodeling through up-regulation of miR-34a.
Li F; Wang D; Wang H; Chen L; Sun X; Wan Y
Respir Res; 2021 Aug; 22(1):239. PubMed ID: 34465322
[TBL] [Abstract][Full Text] [Related]
13. Aspirin attenuates monocrotaline-induced pulmonary arterial hypertension in rats by suppressing the ERK/MAPK pathway.
Gao H; Cheng Y; Zong L; Huang L; Qiao C; Li W; Gong B; Hu J; Liu H; Wang X; Zhao C
Clin Exp Hypertens; 2017; 39(1):34-41. PubMed ID: 28055284
[TBL] [Abstract][Full Text] [Related]
14. Urantide alleviates monocrotaline induced pulmonary arterial hypertension in Wistar rats.
Mei Y; Jin H; Tian W; Wang H; Wang H; Zhao Y; Zhang Z; Meng F
Pulm Pharmacol Ther; 2011 Aug; 24(4):386-93. PubMed ID: 21396478
[TBL] [Abstract][Full Text] [Related]
15. 5-Aminosalicylic Acid Attenuates Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats by Increasing the Expression of Nur77.
Sun LY; Cai ZY; Pu J; Li J; Shen JY; Yang CD; He B
Inflammation; 2017 Jun; 40(3):806-817. PubMed ID: 28213866
[TBL] [Abstract][Full Text] [Related]
16. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats.
Yang PS; Kim DH; Lee YJ; Lee SE; Kang WJ; Chang HJ; Shin JS
Respir Res; 2014 Nov; 15():148. PubMed ID: 25420924
[TBL] [Abstract][Full Text] [Related]
17. A urotensin II receptor antagonist, KR36676, decreases vascular remodeling and inflammation in experimental pulmonary hypertension.
Lee JH; Park BK; Oh KS; Yi KY; Lim CJ; Seo HW; Lee BH
Int Immunopharmacol; 2016 Nov; 40():196-202. PubMed ID: 27611861
[TBL] [Abstract][Full Text] [Related]
18. Dihydromyricetin prevents monocrotaline-induced pulmonary arterial hypertension in rats.
Li Q; Wang J; Zhu X; Zeng Z; Wu X; Xu Y; Xie J; Yu J
Biomed Pharmacother; 2017 Dec; 96():825-833. PubMed ID: 29078260
[TBL] [Abstract][Full Text] [Related]
19. Grape seed proanthocyanidin reverses pulmonary vascular remodeling in monocrotaline-induced pulmonary arterial hypertension by down-regulating HSP70.
Chen F; Wang H; Yan J; Lai J; Cai S; Yuan L; Zheng S
Biomed Pharmacother; 2018 May; 101():123-128. PubMed ID: 29482057
[TBL] [Abstract][Full Text] [Related]
20. Serum-glucocorticoid regulated kinase 1 regulates macrophage recruitment and activation contributing to monocrotaline-induced pulmonary arterial hypertension.
Xi X; Liu S; Shi H; Yang M; Qi Y; Wang J; Du J
Cardiovasc Toxicol; 2014 Dec; 14(4):368-78. PubMed ID: 24825325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]